Ingersoll Rand Total Cost of Revenue decreased by 12.1% to $1.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.9%, from $951.30M to $1.05B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 8.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $766.40M | $810.70M | $909.40M | $810.90M | $870.10M | $940.40M | $969.30M | $965.10M | $989.00M | $999.60M | $1.04B | $923.80M | $1.01B | $1.05B | $1.08B | $951.30M | $1.06B | $1.10B | $1.20B | $1.05B |
| QoQ Change | — | +5.8% | +12.2% | -10.8% | +7.3% | +8.1% | +3.1% | -0.4% | +2.5% | +1.1% | +4.1% | -11.2% | +9.5% | +3.4% | +3.6% | -12.2% | +11.7% | +3.5% | +9.2% | -12.1% |
| YoY Change | — | — | — | — | +13.5% | +16.0% | +6.6% | +19.0% | +13.7% | +6.3% | +7.3% | -4.3% | +2.3% | +4.6% | +4.1% | +3.0% | +5.0% | +5.1% | +10.8% | +10.9% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Industrial Technologies and Services | $729.90M | $824.90M | $848.00M | $944.00M | $814.40M |
| Precision and Science Technologies | $188.60M | $202.40M | $214.40M | $220.20M | $206.00M |
| Total | $951.30M | $1.06B | $1.10B | $1.20B | $1.05B |